

3. N. G. WATON, *Brit. J. Pharmacol.* **11**, 119 (1956).
4. B. SWEDIN, *Acta. med. scand.* **114**, 210 (1943).
5. R. KAPELLER-ADLER, *Biochem. J.* **44**, 70 (1949).
6. R. KAPELLER-ADLER and H. MCFARLANE, *Biochim. biophys. Acta* **67**, 542 (1963).
7. H. M. SINCLAIR, *Biochem. J.* **51**, 10P (1952).
8. A. N. DAVISON, *Biochem. J.* **64**, 546 (1956).
9. D. J. BOULLIN, *Brit. J. Nutr.* **15**, 577 (1961).
10. H. BLASCHKO, C. W. CARTER, J. R. P. O'BRIEN and G. H. S. STANLEY, *J. Physiol. (Lond.)* **107**, 18P (1948).
11. O. GREENGARD and M. GORDON, *Fed. Proc.* **22**, 232 (1963).

Biochemical Pharmacology, 1964, Vol. 13, pp. 805-806. Pergamon Press Ltd., Printed in Great Britain.

A sensitive assay for 5-hydroxytryptophan decarboxylase

(Received 6 February 1964; accepted 3 March 1964)

5-HYDROXYTRYPTOPHAN decarboxylase (5-HTPD) activity is conventionally measured by manometric¹ or fluorometric^{2, 3} techniques. The most sensitive of these methods³ is capable of detecting the formation of 200 μg of serotonin during the incubation period. This report describes a simple, sensitive, and specific radiometric assay for 5-HTPD activity which involves the measurement of ¹⁴C-serotonin formed from DL-5-hydroxytryptophan-¹⁴C. 5-HTPD activity can be routinely determined in tissues which enzymatically produce only 5 μg of the radioactive amine during 1 hr incubation. Fifty or more assays can be performed in 3 hr. 5-HTPD activity has been measured in some tissues for which no quantitative estimates have been previously available.

METHODS

Tissues were homogenized in ice-cold 0.05 M phosphate buffer, pH 7.4. Enzyme preparation (0.1 to 0.6 ml), 0.1 ml of 0.5 M phosphate buffer (pH 7.4), 0.1 ml of a 1 mg/ml solution of iproniazid, and 0.1 ml of a 100 μg /ml pyridoxal phosphate solution and water to make a final volume of 0.9 ml were incubated in a 15-ml glass-stoppered centrifuge tube in air at 37°. After 3 min prior incubation, 11.4 μmoles of DL-5-hydroxytryptophan-¹⁴C (36,000 cpm, 2.64 mc/mm) was added, and the incubation was continued for 30 min. The reaction was stopped by the addition of 0.5 ml of 0.5 M borate buffer, pH 10. The mixture was saturated with sodium chloride, and the ¹⁴C-serotonin formed was extracted by shaking into 6 ml of a 3:2 mixture of 1-butanol and chloroform. After centrifugation, the aqueous layer was aspirated and the organic phase washed with 1 ml of 0.05 M borate buffer, pH 10. Two ml of the resultant organic phase was transferred to a counting vial and evaporated to dryness in a stream of not air. The radioactivity was measured in a liquid scintillation spectrometer after the addition of 3 ml of ethanol and 10 ml of phosphor. Alternatively, the radioactivity in 1 ml of the organic phase was counted directly after the addition of 3 ml of ethanol and 10 ml of phosphor. In this case a correction was made for about 20% quenching. Under these conditions, recovery of ¹⁴C-serotonin added to tissues was 90% ($\pm 4\%$), while less than 0.5% of added DL-5-hydroxytryptophan-¹⁴C was extracted. All values were corrected for heated enzyme blank.

RESULTS AND DISCUSSION

The reaction was linear with time for at least 2 hr and proportional to tissue concentration in liver over a 5-fold concentration range (Table 1) and in all other tissues examined. At high tissue concentrations the enzymatic activity was not linear.

The product of the enzymatic activity was identified as ¹⁴C-serotonin by co-chromatography with the authentic compound in 1-propanol-1 N NH₄OH (75:25) and 1-propanol-1 N acetic acid (75:25).

Specificity was determined by measurement of hepatic 5-HTPD in the presence of dihydroxyphenylalanine, a competitive inhibitor of 5-HTPD. Ninety per cent inhibition was obtained at 10⁻³ M and 63% inhibition at 10⁻⁴ M concentrations of the inhibitor.

5-HTPD activity was estimated in a variety of tissues (Table 2). Pineal gland tissue had the highest enzyme activity, and rat pineal exceeded bovine or quail pineal in activity. These results are in accordance with the extremely high tissue levels (20–100 $\mu\text{g/g}$) of serotonin reported for the rat pineal gland.^{4,5} It is interesting that the rat duodenum is devoid of 5-HTPD activity, whereas the jejunum and ileum

TABLE 1. EFFECT OF TISSUE CONCENTRATION ON THE ENZYMIC FORMATION OF ^{14}C -SEROTONIN

| Liver aliquot (mg) | cpm | ^{14}C -Serotonin (n μmoles formed/mg per hr) |
|-----------------------|----------------|--|
| 0.2 | 261 \pm 8 | 3.92 |
| 0.4 | 536 \pm 9 | 4.02 |
| 0.6 | 798 \pm 21 | 3.99 |
| 1.0 | 1,226 \pm 5 | 3.68 |
| 2.0 | 1,800 \pm 13 | 2.70 |
| 4.0 | 2,268 \pm 40 | 1.70 |

Enzyme preparation, 50 m μmoles pyridoxal phosphate, 0.5 μmoles iproniazid, and 50 μmoles phosphate buffer (pH 7.4) were preincubated for 3 min at 37° in a total volume of 0.5 ml; 11.4 m μmoles of DL-5-hydroxytryptophan- ^{14}C was added and incubation continued for 30 min. Results were corrected for blank values (150 cpm) obtained by incubating DL-5-hydroxytryptophan- ^{14}C with heated enzyme. cpm are expressed as mean \pm average deviation of duplicate samples.

TABLE 2. 5-HYDROXYTRYPTOPHAN DECARBOXYLASE ACTIVITY IN VARIOUS ORGANS

| Organ | ^{14}C -Serotonin (n μmoles formed/g per hr) |
|---------------------|---|
| Rat liver | 3,952 |
| Rat duodenum | 0 |
| Rat jejunum | 1,628 |
| Rat ileum | 1,675 |
| Rat uterus | 16 |
| Rat eye | 6 |
| Rat salivary gland | 2 |
| Rat pineal gland | 12,960 |
| Bovine pineal gland | 6,020 |
| Quail pineal gland | 5,340 |

have high levels. Gaddum and Giarman⁶ examined 5-HTPD in different segments of guinea pig intestine and found that the duodenum has the highest level. The rat uterus, which does not normally have measurable levels of serotonin,⁷ has an active 5-HTPD. This might be expected from the findings of Bogdanski *et al.*⁷ that, after 5-hydroxytryptophan infusion, serotonin levels of 2–4 $\mu\text{g/g}$ could be detected in the rat uterus.

Laboratory of Clinical Science,
National Institute of Mental Health,
Bethesda, Md., U.S.A.

SOLOMON H. SNYDER
JULIUS AXELROD

REFERENCES

1. P. HOLTZ and E. WESTERMANN, Naunyn-Schmiedeberg's *Arch. exp. Path. Pharmacol.* **227**, 538 (1956).
2. A. BERTLER and E. ROSENGREN, *Acta physiol. scand.* **47**, 350 (1959).
3. R. KUNTZMAN, P. A. SHORE, D. BOGDANSKI and B. B. BRODIE, *J. Neurochem.* **6**, 226 (1961).
4. W. QUAY, *Analyt. Biochem.* **5**, 51 (1963).
5. A. PELLEGRINO DE IRALDI, L. M. ZIEHER and E. DEROBERTIS, *Life Sci.* **9**, 691 (1963).
6. J. H. GADDUM and N. J. GIARMAN, *Brit. J. Pharmacol.* **11**, 88 (1956).
7. D. F. BOGDANSKI, H. WEISSBACK and S. UDENFRIEND, *J. Pharmacol. exp. Ther.* **11**, 88 (1956).